---
title: "Alkermes Phase 3 Trial Meets Primary Endpoint for Hypersomnia Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286107593.md"
description: "Alkermes announced that its Phase 3 trial for Lumryz, an oral suspension for treating idiopathic hypersomnia, met all primary and key secondary endpoints. The medication showed significant reductions in excessive daytime sleepiness and improved disease severity compared to placebo. Participants switched to placebo experienced symptom worsening. Alkermes plans to submit a supplemental new drug application to the FDA by year-end. The company's shares rose 1.3% in premarket trading."
datetime: "2026-05-12T13:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286107593.md)
  - [en](https://longbridge.com/en/news/286107593.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286107593.md)
---

# Alkermes Phase 3 Trial Meets Primary Endpoint for Hypersomnia Treatment

09:00 AM EDT, 05/12/2026 (MT Newswires) -- Alkermes ( ALKS ) said Tuesday a late-stage trial evaluating its investigational Lumryz oral suspension in adults with idiopathic hypersomnia, a rare condition in which patients require excessive sleep, met all primary and key secondary endpoints.

The medication demonstrated statistically significant reductions in excessive daytime sleepiness alongside improvements in patient-reported disease severity when compared to a placebo, the company said.

Participants who were switched to a placebo during the withdrawal phase experienced significant symptom worsening compared to subjects who continued treatment, Alkermes ( ALKS ) said.

The company plans to submit a supplemental new drug application to the US Food and Drug Administration by the end of the year, it said.

Shares of the company were up 1.3% in Tuesday premarket activity.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md)

## Related News & Research

- [Alkermes reports encouraging data from Phase III study of Lumryz](https://longbridge.com/en/news/286349759.md)
- [Alkermes Announces Positive Topline Results From Revitalyz Phase 3 Study Evaluating Lumryz](https://longbridge.com/en/news/286085128.md)
- [Wells Fargo Sticks to Its Buy Rating for Alkermes (ALKS)](https://longbridge.com/en/news/286252932.md)
- [Alkermes’ Lumryz, from $2.4B Avadel buy, hits phase 3 mark in IH](https://longbridge.com/en/news/286137280.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)